Brevan Howard Capital Management LP Boosts Stock Position in Charles River Laboratories International, Inc. (NYSE:CRL)

Brevan Howard Capital Management LP lifted its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 90.0% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 8,008 shares of the medical research company's stock after purchasing an additional 3,794 shares during the period. Brevan Howard Capital Management LP's holdings in Charles River Laboratories International were worth $1,478,000 as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. Fiduciary Financial Group LLC raised its stake in Charles River Laboratories International by 3.9% during the fourth quarter. Fiduciary Financial Group LLC now owns 1,665 shares of the medical research company's stock worth $310,000 after purchasing an additional 63 shares during the period. Pinnacle Bancorp Inc. lifted its position in Charles River Laboratories International by 52.0% in the fourth quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company's stock valued at $35,000 after buying an additional 65 shares during the last quarter. Cornerstone Investment Partners LLC boosted its stake in Charles River Laboratories International by 3.7% during the fourth quarter. Cornerstone Investment Partners LLC now owns 1,940 shares of the medical research company's stock worth $358,000 after buying an additional 69 shares during the period. Metis Global Partners LLC increased its position in shares of Charles River Laboratories International by 4.4% during the fourth quarter. Metis Global Partners LLC now owns 1,720 shares of the medical research company's stock valued at $318,000 after acquiring an additional 72 shares during the last quarter. Finally, Two Sigma Securities LLC lifted its holdings in shares of Charles River Laboratories International by 4.3% in the 4th quarter. Two Sigma Securities LLC now owns 1,981 shares of the medical research company's stock worth $366,000 after acquiring an additional 81 shares during the last quarter. Hedge funds and other institutional investors own 98.91% of the company's stock.

Insider Transactions at Charles River Laboratories International

In other news, COO Birgit Girshick acquired 1,514 shares of the business's stock in a transaction on Thursday, February 20th. The shares were acquired at an average price of $164.63 per share, for a total transaction of $249,249.82. Following the completion of the transaction, the chief operating officer now directly owns 55,058 shares of the company's stock, valued at approximately $9,064,198.54. The trade was a 2.83% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO James C. Foster purchased 6,075 shares of the business's stock in a transaction that occurred on Thursday, February 20th. The shares were purchased at an average price of $165.01 per share, for a total transaction of $1,002,435.75. Following the completion of the acquisition, the chief executive officer now directly owns 183,639 shares in the company, valued at $30,302,271.39. The trade was a 3.42% increase in their position. The disclosure for this purchase can be found here. Company insiders own 1.30% of the company's stock.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on CRL shares. JPMorgan Chase & Co. decreased their target price on Charles River Laboratories International from $175.00 to $165.00 and set a "neutral" rating for the company in a report on Thursday, February 20th. Mizuho reduced their target price on shares of Charles River Laboratories International from $175.00 to $155.00 and set a "neutral" rating for the company in a research note on Wednesday, April 9th. William Blair downgraded shares of Charles River Laboratories International from an "outperform" rating to a "market perform" rating in a report on Wednesday, January 22nd. The Goldman Sachs Group cut Charles River Laboratories International from a "buy" rating to a "neutral" rating and lowered their price target for the stock from $190.00 to $170.00 in a report on Friday, March 21st. Finally, Robert W. Baird raised their price target on shares of Charles River Laboratories International from $118.00 to $140.00 and gave the stock a "neutral" rating in a research note on Thursday. One equities research analyst has rated the stock with a sell rating, fifteen have given a hold rating and one has assigned a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus target price of $176.00.

Charles River Laboratories International Price Performance

Shares of CRL traded up $4.54 during midday trading on Monday, hitting $143.33. 649,439 shares of the company traded hands, compared to its average volume of 965,543. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.41 and a quick ratio of 1.14. The stock has a 50-day moving average of $138.40 and a 200-day moving average of $166.20. Charles River Laboratories International, Inc. has a one year low of $91.86 and a one year high of $254.15. The firm has a market cap of $7.04 billion, a P/E ratio of 954.55, a PEG ratio of 4.54 and a beta of 1.50.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The medical research company reported $2.34 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.06 by $0.28. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The company had revenue of $984.17 million for the quarter, compared to analysts' expectations of $942.34 million. During the same quarter in the previous year, the company earned $2.27 earnings per share. Charles River Laboratories International's quarterly revenue was down 2.7% on a year-over-year basis. As a group, sell-side analysts predict that Charles River Laboratories International, Inc. will post 9.36 EPS for the current fiscal year.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).